{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:47:23Z","timestamp":1793677643186,"version":"4.5.1"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"\n Importance<\/jats:title>\n Vasomotor symptoms in perimenopause are associated with increased future cardiovascular (CVD) risk. Most clinical trials on menopausal hormone therapy (MHT) and CVD risk have focused on postmenopausal women, with limited study of the perimenopausal period when hormonal fluctuations and symptoms are greatest. Moreover, these trials were not designed to evaluate CVD risk with MHT among women with vasomotor symptoms.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the effect of MHT on CVD risk among perimenopausal and recently postmenopausal women with vasomotor symptoms and assess the extent to which timing of MHT use relative to menopause and race and ethnicity modify this effect.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Cohort data from the Study of Women\u2019s Health Across the Nation (SWAN, 1997-2017)\u2014a multiethnic, multicenter, longitudinal study of the menopause transition\u2014were used to emulate a sequence of target trials. Eligible participants were women who self-reported any vasomotor symptoms (ie, hot flashes and\/or night sweats over the past 2 weeks) and who were CVD-free, with no prior MHT use. Data were analyzed from January 2023 to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n MHT use (systemic estrogen with\/without progestogens, verified from medication containers).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n CVD events (myocardial infarction, stroke, heart failure, and revascularization) were self-reported. CVD-related death was recorded from death certificates.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 2737 women who reported any vasomotor symptoms, 755 initiated MHT (mean [SD] age, 53.7 [4.6] years) over the 20-year follow-up period, during which 224 fatal and nonfatal CVD events occurred. Overall, the estimated adjusted hazard ratio (aHR) of CVD events for MHT initiation vs noninitiation was 0.78 (95% CI, 0.62-0.98). The estimated aHR was 0.73 (95% CI, 0.58-0.93) and 1.53 (95% CI, 0.66-3.52) among women initiating MHT 10 or fewer years vs more than 10 years from the onset of menopause, respectively (\n P<\/jats:italic>\n value for interaction: .02). Race and ethnicity modified the MHT initiation effect, with Black women showing protective effect (aHR, 0.51; 95% CI, 0.33-0.81), while no clear effects were observed in White women or women of other races (\n P<\/jats:italic>\n value for interaction\u2009=\u2009.007).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The presented results are pooled from all target trials and found that MHT initiation during perimenopause or recently postmenopausal women with vasomotor symptoms was estimated to reduce CVD risk by 22%. Benefits were more pronounced in Black women and women who initiated MHT within 10 years of menopause onset. However, all estimates warrant caution given the potential for residual confounding. Given the inconsistency of the cardiovascular benefits and the need to consider overall risk-benefit balance, these findings should not be used to support MHT for CVD prevention.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.2922","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:00:31Z","timestamp":1788879631000},"page":"1323","source":"Crossref","is-referenced-by-count":1,"title":["Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms"],"prefix":"10.1001","volume":"186","author":[{"given":"Ziyuan","family":"Wang","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja A.","family":"Swanson","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Brooks","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Barinas-Mitchell","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnie","family":"Bertolet","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared W.","family":"Magnani","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania"},{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Thurston","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar R.","family":"El Khoudary","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Public Health, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"ioi260042r1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ogc.2011.05.006","article-title":"Vasomotor symptoms and menopause: findings from the Study of Women\u2019s Health across the nation.","volume":"38","author":"Thurston","year":"2011","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"4","key":"ioi260042r2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition.","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ioi260042r3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00737-007-0209-5","article-title":"Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages.","volume":"10","author":"Deecher","year":"2007","journal-title":"Arch Womens Ment Health"},{"issue":"3","key":"ioi260042r4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"9","key":"ioi260042r5","doi-asserted-by":"publisher","first-page":"e243135","DOI":"10.1001\/jamahealthforum.2024.3135","article-title":"Recent trends in menopausal hormone therapy use in the US: insights, disparities, and implications for practice.","volume":"5","author":"Iyer","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"7","key":"ioi260042r6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group.","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"issue":"7","key":"ioi260042r7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199608153350701","article-title":"Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.","volume":"335","author":"Grodstein","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"ioi260042r8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/gme.0b013e3182014849","article-title":"Vasomotor symptoms and cardiovascular events in postmenopausal women.","volume":"18","author":"Szmuilowicz","year":"2011","journal-title":"Menopause"},{"issue":"13","key":"ioi260042r9","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"ioi260042r10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women\u2019s Health Initiative randomized trials.","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"issue":"13","key":"ioi260042r11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials.","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"ioi260042r12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/jwh.2018.7201","article-title":"The timing hypothesis: hormone therapy for treating symptomatic women during menopause and its relationship to cardiovascular disease.","volume":"28","author":"Mehta","year":"2019","journal-title":"J Womens Health (Larchmt)"},{"issue":"4","key":"ioi260042r13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.7326\/M14-0353","article-title":"Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.","volume":"161","author":"Harman","year":"2014","journal-title":"Ann Intern Med"},{"issue":"13","key":"ioi260042r14","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular effects of early versus late postmenopausal treatment with estradiol.","volume":"374","author":"Hodis","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"ioi260042r15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/GME.0000000000001326","article-title":"The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?","volume":"26","author":"Miller","year":"2019","journal-title":"Menopause"},{"issue":"12","key":"ioi260042r18","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement.","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"ioi260042r19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"3","key":"ioi260042r20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The Target trial framework for causal inference from observational data: why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"issue":"7","key":"ioi260042r22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women\u2019s health across the nation.","volume":"96","author":"Gold","year":"2006","journal-title":"Am J Public Health"},{"issue":"8","key":"ioi260042r23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/GME.0000000000002549","article-title":"Prospective associations of American Heart Association life\u2019s essential 8 with subclinical measures of vascular health, cardiovascular disease events, and all-cause mortality in women traversing menopause: the Study of Women\u2019s Health Across the Nation.","volume":"32","author":"Wang","year":"2025","journal-title":"Menopause"},{"issue":"24","key":"ioi260042r24","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"ioi260042r25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology"},{"issue":"1","key":"ioi260042r26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research.","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"issue":"18","key":"ioi260042r27","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/jama.2015.15281","article-title":"Multiple imputation: a flexible tool for handling missing data.","volume":"314","author":"Li","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"ioi260042r28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/STROKEAHA.115.010600","article-title":"Trajectories of vasomotor symptoms and carotid intima media thickness in the Study of Women\u2019s Health Across the Nation.","volume":"47","author":"Thurston","year":"2016","journal-title":"Stroke"},{"issue":"6","key":"ioi260042r29","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/GME.0000000000001282","article-title":"Menopausal hormone therapy trends before versus after 2002: impact of the Women\u2019s Health Initiative Study Results.","volume":"26","author":"Crawford","year":"2018","journal-title":"Menopause"},{"issue":"6","key":"ioi260042r30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/GME.0000000000001294","article-title":"Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17\u00df-estradiol\/progesterone.","volume":"26","author":"Mirkin","year":"2019","journal-title":"Menopause"},{"key":"ioi260042r31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.maturitas.2022.06.008","article-title":"Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States.","volume":"164","author":"Stute","year":"2022","journal-title":"Maturitas"},{"issue":"6","key":"ioi260042r32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.mayocp.2023.02.025","article-title":"Impact of menopause symptoms on women in the workplace.","volume":"98","author":"Faubion","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"ioi260042r33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1477-7525-3-47","article-title":"Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.","volume":"3","author":"Utian","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"ioi260042r34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/GME.0000000000002237","article-title":"Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey.","volume":"30","author":"DePree","year":"2023","journal-title":"Menopause"},{"issue":"1","key":"ioi260042r35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/GME.0000000000002095","article-title":"Treatment and resource utilization for menopausal symptoms in the United States: a retrospective review of real-world evidence from US electronic health records.","volume":"30","author":"DePree","year":"2023","journal-title":"Menopause"},{"issue":"3","key":"ioi260042r36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017416","article-title":"Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN.","volume":"10","author":"Thurston","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"ioi260042r37","doi-asserted-by":"publisher","first-page":"898.e1","DOI":"10.1016\/j.ajog.2020.06.039","article-title":"Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.","volume":"223","author":"Zhu","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"ioi260042r38","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jamainternmed.2025.4510","article-title":"Menopausal hormone therapy and cardiovascular diseases in women with vasomotor symptoms: a secondary analysis of the Women\u2019s Health Initiative randomized clinical trials.","volume":"185","author":"Rossouw","year":"2025","journal-title":"JAMA Intern Med"},{"key":"ioi260042r39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078784","article-title":"Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial.","volume":"387","author":"Johansson","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"ioi260042r40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002229.pub4","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women.","volume":"2015","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ioi260042r41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/GME.0000000000000733","article-title":"Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial.","volume":"24","author":"Chlebowski","year":"2017","journal-title":"Menopause"},{"issue":"10","key":"ioi260042r42","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/HJH.0000000000000287","article-title":"The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women\u2019s Health Initiative randomized controlled trials.","volume":"32","author":"Shimbo","year":"2014","journal-title":"J Hypertens"},{"issue":"7","key":"ioi260042r43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society.","volume":"29","author":"The North American Menopause Society Advisory Panel","year":"2022","journal-title":"Menopause"},{"key":"ioi260042r21","volume-title":"Menopause: Biology and pathobiology","author":"Sowers","year":"2000"},{"key":"ioi260042r16","unstructured":"US Food and Drug Administration. Estrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms\u2014Recommendations for Clinical Evaluation. Accessed January 7, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy"},{"key":"ioi260042r17","unstructured":"US Food and Drug Administration. HHS advances women\u2019s health, removes misleading FDA warnings on hormone replacement therapy. Accessed January 7, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2853611\/jamainternal_wang_2026_oi_260042_1792166576.76058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:01:00Z","timestamp":1793635260000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2853611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.2922","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}